Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Event: Guggenheim 3^rd Annual Healthcare Innovation Conference
Date: November 9-11, 2026
Fireside Date/Time: Monday, November 9^th at 9:00am ET

Event: Jefferies London Healthcare Conference
Date: November 16-19, 2026
Fireside Date/Time: Thursday, November 19^th at 1:00pm GMT

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim and Jefferies representatives.

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.

Contacts:

Christen Baglaneas 
Rezolute, Inc. 
1411 Broadway, 16th Floor 
New York, NY 10018 
cbaglaneas@rezolutebio.com 
508-272-6717 

Carrie McKim 
Rezolute, Inc. 
1411 Broadway, 16th Floor 
New York, NY 10018 
cmckim@rezolutebio.com  
336-608-9706